Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Market Cap	2.27B -19.0%
Revenue (ttm)	977.79M -35.5%
Net Income	-102.95M
EPS	-2.61
Shares Out	76.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.19 (0.67%)
Ex-Dividend Date	Jul 24, 2025

Volume	169,458
Average Volume	288,805
Open	28.85
Previous Close	28.70
Day's Range	28.85 - 29.55
52-Week Range	23.50 - 33.95
Beta	0.51
RSI	59.86
Earnings Date	Mar 27, 2026

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DMF or COS, and other API products. It also provides specialty API immunosuppressants, including mycophenolate mofetil, rapamycin, and tacrolimus; deriva...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1964
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1762

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.